The Alliance for Regenerative Medicine (ARM) today announced the release of its 2017 Annual Data Report, offering an in-depth look at trends and metrics for the cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector.
Using data provided by ARM’s data partner Informa, curated and further analyzed by ARM’s staff, the report details industry-specific statistics and trends from more than 850 leading cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide.
ARM Global Regenerative & Advanced Therapy Medicine Sector Report: H1 2020
Despite the unprecedented global challenge presented by COVID-19, the regenerative medicine and advanced therapy sector demonstrated remarkable resilience in the first half of 2020. Patients continued to benefit from the cell and gene therapies currently on the market and in trials, and investment in the sector was robust. Policymakers and regulators recognize the need to continue to promote development for durable and potentially curative therapies for patients with unmet medical needs outside of COVID-19, though challenges remain. The H1 report provides an overview of the current financial, clinical, and policy landscape for these innovative treatments, with commentary from leading experts on the sector.
ARM Annual Report & Sector Year in Review: 2019
The 2019 ARM Annual Report provides an overview of the organizations events, publications, and policy initiatives over the last year, with commentary from ARM members. In addition, the report contains a global sector overview detailing industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, and clinical trial information.